Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Adults With Overweight and Obesity
Latest Information Update: 28 May 2025
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms STEP12
- Sponsors Novo Nordisk
Most Recent Events
- 21 May 2025 Status changed from active, no longer recruiting to completed.
- 19 Sep 2024 Planned number of patients changed from 162 to 242.
- 02 Jul 2024 Planned End Date changed from 11 Jun 2025 to 7 May 2025.